- Home
- ALGS vs ATRA Comparison
ALGS vs ATRA Comparison
Compare ALGS & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- ATRA
- Stock Information
- Founded
- ALGS 2018
- ATRA 2012
- Country
- ALGS United States
- ATRA United States
- Employees
- ALGS N/A
- ATRA N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALGS Health Care
- ATRA Health Care
- Exchange
- ALGS Nasdaq
- ATRA Nasdaq
- Market Cap
- ALGS 38.8M
- ATRA 42.5M
- IPO Year
- ALGS 2020
- ATRA 2014
- Fundamental
- Price
- ALGS $7.14
- ATRA $6.01
- Analyst Decision
- ALGS Strong Buy
- ATRA Buy
- Analyst Count
- ALGS 1
- ATRA 6
- Target Price
- ALGS $70.00
- ATRA $25.70
- AVG Volume (30 Days)
- ALGS 140.5K
- ATRA 50.2K
- Earning Date
- ALGS 03-10-2025
- ATRA 05-08-2025
- Dividend Yield
- ALGS N/A
- ATRA N/A
- EPS Growth
- ALGS N/A
- ATRA N/A
- EPS
- ALGS N/A
- ATRA N/A
- Revenue
- ALGS $3,945,000.00
- ATRA $128,940,000.00
- Revenue This Year
- ALGS $580.86
- ATRA N/A
- Revenue Next Year
- ALGS N/A
- ATRA $43.69
- P/E Ratio
- ALGS N/A
- ATRA N/A
- Revenue Growth
- ALGS N/A
- ATRA 1404.02
- 52 Week Low
- ALGS $6.76
- ATRA $5.40
- 52 Week High
- ALGS $46.80
- ATRA $20.83
- Technical
- Relative Strength Index (RSI)
- ALGS 24.28
- ATRA 36.60
- Support Level
- ALGS $10.45
- ATRA $6.53
- Resistance Level
- ALGS $9.76
- ATRA $6.90
- Average True Range (ATR)
- ALGS 1.11
- ATRA 0.43
- MACD
- ALGS 0.15
- ATRA -0.00
- Stochastic Oscillator
- ALGS 2.13
- ATRA 16.32
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).